Das Multiples Myelom: Pflege entlang der Krankheitsverlaufskurve

Krebs wird zunehmend als chronische Erkrankung angesehen. Ein gutes Beispiel ist das Multiple Myelom. Durch den medizinischen Fortschritt kann es in vielen Fällen über lange Jahre sehr gut kontrolliert werden. Ein wichtiges Modell für die Betreuung chronisch Kranker ist die Krankheitsverlaufskurve. Sie hilft, den Pflegebedarf auf die verschiedenen Krankheitsphasen abzustimmen und Betroffene auf die Herausforderungen folgender Phasen vorzubereiten.

Schlüsselwörter

Multiples Myelom - MM - Krankheitsverlaufskurve - chronische Erkrankung - onkologische Pflege

• Literatur

• 1 Mey UJM, Leitner C, Driessen C. et al. Improved survival of older patients with multiple myeloma in the era of novel agents. Hematol Oncol 2016; 34: 217-223
• 2 Corbin JM, Strauss AL. Weiterleben lernen: Verlauf und Bewältigung chronischer Krankheit. Bern/Göttingen: Huber; 2010
• 3 Friese CR, Abel GA, Magazu LS. et al. Diagnostic delay and complications for older adults with multiple myeloma. Leuk Lymphoma 2009; 50: 392-400
• 4 Howell DA, Hart RI, Smith AG. et al. Myeloma: patient accounts of their pathways to diagnosis. PloS one 2018; 13: e0194788
• 5 Zabora J, Buzaglo J, Kennedy V. et al. Clinical perspective: linking psychosocial care to the disease continuum in patients with multiple myeloma. Palliat Support Care 2015; 13: 829-838
• 6 Naegele M, Neumann M. Information needs of myeloma patients along the illness trajectory. Clin Lymphoma Myeloma Leuk 2019; 19: e344-e345
• 7 Kortuem KM, Engelhardt M, Rasche L. et al. Das multiple Myelom. Internist 2013; 54: 963-977
• 8 Colson K. Treatment-related symptom management in patients with multiple myeloma: a review. Support Care Cancer 2015; 23: 1431-1445
• 9 Wäsch R, Jakob T, Technau K. et al. Stevens–Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation. Ann Hematol 2012; 91: 287-289
• 10 Dimopoulos MA, Moreau P, Terpos E. et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2021; 32: 309-322
• 11 Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 2011; 10: 2034-2042
• 12 Ludwig H, Delforge M, Facon T. et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the european myeloma network. Leukemia 2017;
• 13 Martin JR, Beegle NL, Zhu Y. et al. Subcutaneous administration of bortezomib: a pilot survey of oncology nurses. J Adv Pract Oncol 2015; 6: 308-18
• 14 Fujimoto Y, Ueno S, Oda K. et al. Relationship between serum bortezomib concentration and emergence of diarrhea in patients with multiple myeloma and/or AL amyloidosis. Cancers 2021; 13: 5674
• 15 Naegele M, Kirsch M, Ihorst G. et al. Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study. Support Care Cancer 2018; 26: 833-841
• 16 Leppla L, Naegele M, Rebafka A. et al. Orale Kryotherapie bei Patienten mit Hochdosis Melphalangabe vor autologer Stammzelltransplantation. Onkologische Pflege. 2016
• 17 Bennink C, Klift M, Scheurer H. et al. Perspectives on returning to work of multiple myeloma patients: a qualitative interview study. Eur J Cancer Care 2021; 30: e13481
• 18 Sabaté E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003
• 19 Naser AY, Ofori-Asenso R, Awawdeh SA. et al. Real world adherence to and persistence with oral oncolytics in multiple myeloma: A systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk 2022; 22 (10) 760-773
• 20 Kav S, Schulmeister L, Nirenberg A. et al. Development of the MASCC teaching tool for patients receiving oral agents for cancer. Support Care Cancer 2010; 18: 583-90
• 21 König C, Kleber M, Reinhardt H. et al. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients. Ann Hematol 2014; 93: 479-484
• 22 Pawlyn C, Khan MS, Muls A. et al. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood 2014; 124: 2467-2468
• 23 Shields JL, Englert B, Passero VA. Dispensing and monitoring oral anticancer therapy. Federal Practitioner 2015; 32: 38S-41S
• 24 Boland E, Eiser C, Ezaydi Y. et al. Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. J Pain Symptom Manage 2013; 46: 671-680
• 25 Nathwani N, Bell J, Cherepanov D. et al. Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma. Support Care Cancer 2022; 30: 5859-5869
• 26 Buitrago J, Adkins S, Hawkins M. et al. Adult survivorship: considerations following CAR T-cell therapy. CJON 2019; 23: 42-48
• 27 Cormican O, Dowling M. Living with relapsed myeloma: symptoms and self‐care strategies. J Clin Nurs 2018; 7: 1713-1721
• 28 Dodd M, Janson S, Facione N. et al. Advancing the science of symptom management. J Clin Nurs 2001; 33: 668-676
• 29 Naegele M. Symptommanagement – pflegewissenschaftliche Modelle in der Theorie und Praxis. Onkologe 2020; 26: 998-1009
• 30 National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. 2017. . Zugriff am 20. September 2022 unter: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5×7.pdf